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a b s t r a c t 
Background: In 2012, Fiji became the first independent Pacific island country to introduce rotavirus vac- 
cine. We describe the impact of rotavirus vaccine on all-cause diarrhoea admissions in all ages, and ro- 
tavirus diarrhoea in children < 5 years of age. 
Methods: An observational study was conducted retrospectively on all admissions to the public tertiary 
hospitals in Fiji (2007–2018) and prospectively on all rotavirus-positive diarrhoea admissions in children 
< 5 years at two hospital sites (2006–2018, and 2010–2015), along with rotavirus diarrhoea outpatient 
presentations at one secondary public hospital (2010–2015). The impact of rotavirus vaccine was deter- 
mined using incidence rate ratios (IRR) of all-cause diarrhoea admissions and rotavirus diarrhoea, com- 
paring the pre-vaccine and post-vaccine periods. All-cause admissions were used as a control. Multiple 
imputation was used to impute missing stool samples. 
Findings: All-cause diarrhoea admissions declined among all age groups except among infants ≤2 
months old and adults ≥55 years. For children < 5 years, all-cause diarrhoea admissions declined by 39% 
(IRR) = 0 • 61, 95%CI; 0 • 57–0 • 65, p -value < 0 • 001). There was an 81% (95%CI; 51–94%) reduction in mortality 
among all-cause diarrhoea admissions in children under < 5 years. Rotavirus diarrhoea admissions at the 
largest hospital among children < 5 years declined by 87% (IRR = 0 • 13, 95%CI; 0 • 10–0 • 17, p -value < 0 • 001). 
Among rotavirus diarrhoea outpatient presentations, the IRR was 0 • 39 (95%CI; 0 • 11, 1.21, p -value = 0.077). 
Interpretations: Morbidity and mortality due to rotavirus and all-cause diarrhoea in Fiji has declined in 
people aged 2 months to 54 years after the introduction of the RV vaccine. 
Funding: Supported by WHO and the Australian Government. 
© 2020 The Authors. Published by Elsevier Ltd. 
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Beyond the neonatal period, diarrhoea is the second common- 
st cause of death in children less than five years old, worldwide 
1] . Without vaccination, rotavirus causes approximately 38% of 
ll diarrhoea admissions in children < 5 years old [2] . Two vac- 
ines became available in 2006 [3] and yet in 2015 there were still 
99,0 0 0 diarrhoeal deaths in children due to rotavirus [4] . Approx- 
mately 45% of infants do not have access to the vaccine [5] and 
o rotavirus remains common [6] . However, where the vaccine has 
een introduced into low- and middle-income countries (LMIC), 
he Global Rotavirus Surveillance Network has reported a 39 • 6% 
eduction in diarrhoea admissions [2] . Rotavirus vaccine impact is 
lso evident among outpatients, where most of the cases are seen 
7] . 
Island nations in the Pacific may particularly benefit from the 
otavirus vaccine due to the risk of severe rotavirus outbreaks [ 8 , 9 ].
owever, with the exception of Fiji and the Philippines, the burden 
f rotavirus in the Asia-Pacific region is largely unknown [10-12] . 
n October 2012, Fiji was the first independent Pacific Island coun- 
ry to introduce rotavirus vaccine into the national immunisation 
chedule. This decision was based on our previous findings that 
9% of diarrhoea admissions in children < 5 years of age, particu- 
arly indigenous (iTaukei) Fijian children, prior to vaccine introduc- 
ion were due to rotavirus [10] . In order to inform future policy 
ecisions in Fiji and other Pacific islands we undertook a study to 
escribe rotavirus diarrhoea inpatient and outpatient attendances 
efore and after the national introduction of rotavirus vaccine in 
hildren; and all-cause diarrhoea admission rates, in all ages, na- 
ionwide. 
. Methods 
.1. Study setting and design 
Fiji is an upper-middle income Pacific island country of 884,887 
2017 census) of whom 55 • 9% reside in an urban setting [13] . The
thnic distribution of residents in Fiji for 2017 was 62% iTaukei, 
2% Fijian of Indian descent and 6% other, estimated from the 
007 census data with ethnicity specific growth rates applied [14] . 
omen comprise 49% of the population [14] . In 2017, the post 
eonatal infant mortality rate in Fiji was 11 per 10 0 0 live births
15] . Malnutrition rates among children < 5 years were 7.5%, 6.3% 
nd 5.1% for stunting, wasting and overweight respectively when 
ast published in 2004 [16] . 
In October 2012, the Government of Fiji introduced into the 
ational immunisation schedule; the monovalent rotavirus vaccine 
Rotarix, GlaxoSmithKline) as a two-dose schedule at six and 14 
eeks of age and the 10-valent pneumococcal conjugate vaccine 
Synflorix, GlaxoSmithKline) as a three-dose schedule at six, 10 and 
4 weeks of age. National vaccine coverage estimates for two doses 
f rotavirus vaccine were 85%, 91%, 94%, 93% and 98% in 2013, 
014, 2015, 2016 and 2017, respectively [17] . 
The percentage of all admissions in Fiji between 2007 and 2017 
o the three tertiary hospitals were; 37% Colonial War Memorial 
ospital (CWMH), Suva, 19% Lautoka, 11% Labasa, and 33% were 
o secondary hospitals. Upon admission to a tertiary hospital, pa- 
ients’ details are recorded into the ward registers by a nurse. 
octors manually record clinical notes, including discharge diag- 
oses. Coders assign an ICD-10-AM code for each discharge diagno- 
is, which are entered, with the other clinical information into the 
omputerised national hospital admission database (PATIS) which 
enerates a patient’s unique National Health Number (NHN). The 
ATIS system has been available at all three tertiary hospitals from 
007 and has been demonstrated in a previous study to be 89% 
omplete [18] . 2 This is an observational study describing all-cause diarrhoea ad- 
issions nationwide in all ages at all three public tertiary hospitals 
CWMH, Lautoka, Labasa) and rotavirus diarrhoea in < 5-year olds 
t two hospital-based sentinel sites: the largest tertiary hospital 
or admissions CWMH, and one secondary public hospital for ad- 
issions and outpatients, Savusavu Hospital. 
.2. National all-cause diarrhoea admission data 
Hospital admission data for all-causes of illness were retrospec- 
ively extracted from PATIS for people of all ages between 2007 
nd 2017. All-cause diarrhoea admissions and all-cause admissions 
used as a control group to assess if changes in the post-rotavirus 
accine period were due to changes in access to care) were clas- 
ified according to primary discharge diagnosis using ICD-10-AM 
odes; all-cause diarrhoea were ICD-10-AM codes: A0-A2.1, A2.3- 
6.3, A6.9-A9, A9.9, K52.9. All-cause admissions were all ICD-10- 
M codes excluding those relating to diarrhoea (A0-A2.1, A2.3- 
6.3, A6.9- A9, A9.9, K52.9), pneumonia (all ‘J’ codes – as the pneu- 
ococcal conjugate vaccine was introduced simultaneously with 
he rotavirus vaccine and reductions in pneumonia admissions 
ave been found), child birth (all ‘O’ codes) and mental health (all 
F’ codes). Readmissions for any cause within 30 days were identi- 
ed by NHN and excluded as the second admission was consid- 
red the same episode of illness. Any child discharged with di- 
rrhoea representing with subsequent malnutrition (or any other 
ondition that did not have the ICD10 code for diarrhoea, pneumo- 
ia and pneumococcal related disease) on day 31 or after, would 
e counted as a case, and subsequently as a control condition. 
.3. Sentinel site surveillance 
There were two rotavirus diarrhoea surveillance sites: CWMH, 
erving an estimated population of 34,920 children < 5 years of 
ge (38% of Fiji’s total) [13] in 2017; and Savusavu Hospital serv- 
ng 6563 semi-urban and rural children < 5 years of age (7% of the 
ational total) [13] . Population data was sourced from the Fiji Bu- 
eau of Statistics 2007 census as the 2017 census did not record 
thnicity and our time period of analysis started in 2006. The pop- 
lation data was adjusted for population growth by multiplying the 
ge and ethnic specific population data from the previous year by 
he ethnic specific annual growth rate; + 1.7% for iTaukei, −1.7% for 
ijians of Indian descent and + 0.7% for others [14] . 
To obtain data on rotavirus positive outcomes, a diarrhoea 
rospective surveillance system was established in December 2005 
t CWMH. Cases were identified daily (by our research staff
onday-to-Friday and ward nursing staff on weekends), through 
hecking paediatric ward registers and PATIS to ensure all cases 
ere included. Identifiers were checked and any duplicates were 
emoved. Children < 5 years of age admitted to the CWMH with 
on-bloody diarrhoea (defined as 3 or more looser than nor- 
al stools [without blood] within 24 h of admission, based on 
arental report) were enroled. Demographic and clinical data were 
ecorded; age, ethnicity, sex, length of stay in hospital, treatment, 
eath in hospital. Nurses or parents collected stool samples within 
8 h of admission. Ethnicity was self-reported in surveillance and 
ATIS. For the surveillance at CWMH between December 2005 to 
une 2012 all enrolment procedures were done by study staff. In 
une 2012 Ministry of Health and Medical Services (MoHMS) col- 
ected the data. The nurse-in-charge oversaw enrolment and study 
taff monitored stool and data collection daily (Monday-to-Friday). 
tool samples were stored (4–8 °C) prior to transportation to the 
iji Centre for Communicable Disease Control in Suva (15 min drive 
rom CWMH). 
Similarly, at Savusavu Hospital, children (both inpatients and 
utpatients) were enroled between March 2010 and December 
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Table 1 
Years included in the pre- and post-rotavirus vaccination period by site and outcome. 
Outcome Site Pre-vaccination period Post-vaccination period 
All-cause diarrhoea admissions National January 2007 to December 2011 January 2014 to December 2017 
All-cause diarrhoea admissions CWMH January 2006 to December 2011 January 2014 to December 2018 
RV diarrhoea admissions CWMH January 2006 to December 2011 January 2014 to December 2018 
RV diarrhoea admissions Savusavu May 2010-December 2011 January 2014 to December 2015 
RV diarrhoea outpatient presentations Savusavu May 2010-December 2011 January 2014 to December 2015 
RV = rotavirus. 



























































































016. Cases were identified from admission notes and ward reg- 
stration (as PATIS is unavailable in Savusavu). A study-appointed 
echnical assistant oversaw the surveillance and undertook; data 
ollection, stool collection and storage. Stool samples were stored 
t −20 °C and transported to the Fiji Centre for Communicable Dis- 
ase Control in Suva using ice packs every three months. 
At the Fiji Centre for Communicable Disease Control in Suva 
tool samples were stored at −70 °C or −20 °C depending on the 
vailability of space and tested in batches on a three-monthly 
asis. Rotavirus antigen was detected using the ProSpecT Ro- 
avirus microplate assay (Oxoid, Basingstoke, Hampshire, UK). 
pecimens were sent on dry ice to the regional reference labora- 
ory (RRL), Murdoch Children’s Research Institute, Melbourne on a 
ix-monthly basis, where real-time multiplex PCR was used to con- 
rm the presence of rotavirus and determine the virus genotype 
19] . Genotyping results will be presented elsewhere. 
.4. Surveillance monitoring 
At both sites monitoring was conducted by a study staff, on a 
aily (Monday to Friday) basis at CWMH and a quarterly basis at 
avusavu. A diarrhoea case identified post-discharge, was enroled 
etrospectively noting the absence of stool collection. 
.5. Data analysis 
The years defining the pre-rotavirus vaccination period are dis- 
layed in Table 1 , with justification for years selected in the sup- 
lementary material. Full calendar years were used due to the sea- 
onality, except for Savusavu where all available pre-rotavirus vac- 
ine data was used (as the study period there was relatively short). 
Age-stratified analyses were planned a priori (e.g. to allow com- 
arisons across studies, or to enable assessment of incidence rates 
n vaccinated and unvaccinated age groups). Age groups were; in- 
ants too young to be vaccinated ≤2 months of age, infants fully 
accinated 1–11 months of age, < 1 year of age, 1–2 years of age
o determine waning in the second year of life, 2–4 years of age, 
 5 years of age, 5–9 years of age (unvaccinated and most likely 
o benefit for indirect effects in the household), 10–19 years of age 
preteen and adolescents), 20–54 years of age (caregivers) and ≥55 
ears of age (elderly in this population). 
Demographic characteristics were compared between those 
ith and without stool specimens using a chi squared test of as- 
ociation for binary data and Wilcoxon rank-sum for continuous 
ata. 
Incidence rates were calculated as the number of cases, divided 
y the population, multiplied by 10 0,0 0 0 with exact Poisson confi- 
ence intervals. The incidence rate ratio post/pre-rotavirus vaccine 
as calculated using Poisson regression with rotavirus counts as 
he outcome variable and period (pre-vaccine vs. post-vaccine) as 
 covariate: thus providing an overall estimate of vaccine impact. 
he logarithm of the population denominators was included in the 
odel as an offset variable. The model coefficients were exponen- 
iated to obtain incidence rate ratios (with corresponding 95% con- 
dence intervals and p -values). We considered subgroup analysis 3 y ethnicity to examine whether declines in incidence rates were 
ifferent between ethnic groups. To determine whether to present 
thnicity-stratified analyses, we included terms for the interaction 
etween ethnicity and vaccine period in our models. To do this 
e fitted Poisson regression models with counts of rotavirus pos- 
tive cases as the outcome variable, and vaccine period (baseline 
s. post-vaccination), ethnicity and an interaction term as covari- 
tes, and used a p -value of 0.05 as the significance level for inter- 
ctions. When investigating interactions, ethnicity was treated as 
 binary variable (iTaukei vs. Fijian of Indian descent); the “other”
roup was omitted due to small numbers and the diversity within 
his group. The outcome ‘all-cause admissions’ was analysed using 
he same method and used as a control to assess changes in hos- 
ital admissions during the period of analysis. 
We performed two sensitivity analyses; the first, to adjust for 
ases without a stool sample collected, was multiple imputation 
o handle missing data for a rotavirus test result. The second ad- 
usted for changes in trends over the years not associated with 
he vaccine, i.e. an interrupted time series regression analysis of 
ational all-cause diarrhoea admissions in children < 5 years, the 
nly outcome among young children with enough data points for 
ime-series analysis. Full methods of both sensitivity analyses are 
escribed in the supplementary material. 
The case fatality rates (CFR) were calculated for children aged 
–59 months of age admitted to CWMH with all-cause diarrhoea, 
s the number of deaths in hospital among children admitted with 
ll-cause diarrhoea divided by the number of children admitted for 
ll-cause diarrhoea multiplied by 100, with exact Poisson confi- 
ence intervals. All data were analysed using STATA 15 • 1 (Stata- 
orp LP, Texas, USA). 
The manuscript has been prepared according to the STROBE 
STrengthening the Reporting of OBservational studies in Epidemi- 
logy) checklist. 
.6. Ethics approval 
Ethical approval for these studies was obtained from the Fiji Na- 
ional Research Ethics Review Committee (number 2013 • 40) and 
rom the University of Melbourne Human Research Ethics Com- 
ittee for the initial study surveillance in CWMH 2005–2012 
Ethics ID: 050546X) and Savusavu from 2010 to 2012 (Ethics ID: 
931282), during this period written informed consent was ob- 
ained from the participants’ parents. From June 2012, the MoHMS 
onsidered this public health surveillance no longer required writ- 
en consent. Retrospective data extracted from PATIS was deidenti- 
ed. 
.7. Role of the funding source 
This work was supported by the World Health Organisation to 
et up the initial study (2005–7) and an additional World Health 
rganisation grant [Registry File No. V27-181-188] for data col- 
ected between 2006 and 2013. A Merck investigator-initiated grant 
IISP ID#: 35,248) funded the early work in Savusavu (2009–10). 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































. ata collection between 2014 and 2018 and the final analysis was 
upported by the Department of Foreign Affairs and Trade of the 
ustralian Government and Fiji Health Sector Support Program 
FHSSP). FHSSP is implemented by Abt JTA on behalf of the Aus- 
ralian Government. Funders had no role in study design, data col- 
ection, data analysis, interpretation, writing of the report. RR had 
ull access to study data and AWJJ had final responsibility for the 
ecision to submit for publication. 
. Results 
.1. Description of data and demographics 
There were 8851 all-cause diarrhoea admissions nationally for 
ll ages between 2007 and 2017 ( Table 2 ). National all-cause di- 
rrhoea admissions were more common among the iTaukei (6279, 
1%) population vs. Fijians of Indian descent (2164, 25%), and less 
ommon among males (3886, 44%) than females as compared to 
he population distribution as described in the methods ( Table 2 ). 
Between 2007–2017, 71% (3087/4353) of nationwide all-cause 
iarrhoea admissions among children < 5 years of age occurred at 
WMH. Stool sample testing rates in the pre- vs. post-rotavirus 
accine period were 80% (1498/1854) vs. 57% 9586/1037) p - 
alue < 0.001; 52% (44/84) vs. 97% (38/39) p -value < 0.001; and 
3% (79/347) vs. 83% (432/520) p -value < 0.001, at CWMH, Savusavu 
npatients and outpatients, respectively (Supplementary Table 1). 
mong CWMH cases 60% (3/5) of the demographic or clinical char- 
cteristics differed between those with and without stool sample 
ollected; the former were slightly older; 14 months (interquartile 
ange (IQR); 8–24 m) vs. 12 months (IQR; 7–23 m) p -value = 0.056;
ad a longer periods of admission; two days (IQR; 1–40 days) 
s. two days (IQR; 1–4 days) p -value < 0.001; were less likely to 
ave received intravenous fluid; 417 (53.4%) vs. 1246 (65.4%) p - 
alue < 0.001. Rotavirus positivity rates at CMWH using the raw 
ata were 39.9% (599/1498) and 12.3% (72/586) in the pre- and 
ost-rotavirus vaccine periods, respectively and using the multiple 
mputation data were 39.2% (95%CI: 1.3 to 36.7) and 11.8% (95%CI: 
.2 to 14.4%) in the pre- and post-rotavirus vaccine periods, respec- 
ively. 
.2. Vaccine impact on national all-cause diarrhoea admissions 
All-cause diarrhoea admissions declined in the post-rotavirus 
accine period among all age groups except infants ≤2 months 
ld and adults ≥55 years, where it increased ( Table 3 , Fig. 1 and
upplementary Table 2). The time-series analysis suggests a stable 
ackground trend in diarrhoea over time (IRR = 1.00 (1.00, 1.01) for 
he monthly change in diarrhoea rates), and an estimated 52.3% 
95% CI: 27.7% to 68.5%) decrease in monthly all-cause diarrhoea 
dmissions following vaccine introduction (Supplementary Table 3 
nd Supplementary Fig. 1). Full results of are presented in the sup- 
lementary materials. 
All-cause admissions (the control) increased in all age groups 
part from the 10–19 years (where there was no change) and 
2 months age group where admissions declined. For all the age 
roups that included infants ≤2 months, namely: ≤2months, < 1 
ear, < 5 years and the total population; there were also declines 
n all-cause admissions ( Fig. 1 and Supplementary Table 2). 
.3. Vaccine impact on rotavirus positive diarrhoea admissions 
Rotavirus diarrhoea admissions at CWMH among children < 5 
ears declined by 87% in the post-rotavirus vaccine period (in- 
idence rate ratio (IRR) = 0 • 13, 95%CI; 0 • 10–0 • 17, p -value < 0 • 001)
 Fig. 1 and Supplementary Table 2). The greatest impact was 4 
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Table 3 
Mean annual cases and incidence rates in the pre- and post-rotavirus vaccine periods in Fiji, and incidence rate ratios estimating post/pre-rotavirus vaccine, 
by outcome and age group. 
Mean annual cases IR /10 0,0 0 0 (95% CI) a IRR (95% CI) P-value 
Pre-RV vaccine Post-RV vaccine Pre-RV vaccine Post-RV vaccine 
National all-cause diarrhoea admissions 
< 1yr 175.8 107.0 1050 (982, 1121) 615 (558, 676) 0.59 (0.52, 0.66) < 0.001 
1–2yrs 148.0 84.0 884 (822, 950) 483 (432, 537) 0.55 (0.48, 0.62) < 0.001 
3–4yrs 158.0 117.0 315 (293, 337) 224 (204, 245) 0.71 (0.63, 0.80) < 0.001 
5–9yrs 85.6 57.0 108 (98, 119) 69 (61, 79) 0.64 (0.54, 0.75) < 0.001 
10–19yrs 79.4 47.0 48 (44, 53) 28 (24, 32) 0.57 (0.48, 0.68) < 0.001 
20–54yrs 194.8 163.0 46 (43, 49) 37 (34, 40) 0.80 (0.73, 0.89) < 0.001 
≥55y 78.8 95.5 83 (75, 91) 96 (87, 107) 1.17 (1.01, 1.35) 0.017 
Total population 920.4 670.5 109 (106, 112) 76 (73, 79) 0.70 (0.67, 0.74) < 0.001 
RV diarrhoea admissions at CWMH 
≤2m 1.6 0.5 126 (54, 248) 35 (4, 126) 0.28 (0.03, 1.38) 0.090 
< 1yr 55.6 4.8 731 (647, 821) 70 (45, 103) 0.10 (0.06, 0.14) < 0.001 
1–2yrs 41.2 5.2 541 (470, 620) 75 (49, 110) 0.14 (0.09, 0.21) < 0.001 
3–4yrs 23.0 4.0 101 (83, 121) 19 (12, 30) 0.19 (0.11, 0.31) < 0.001 
< 5yrs 119.8 14.0 315 (290, 341) 41 (32, 51) 0.13 (0.10, 0.17) < 0.001 
RV diarrhoea at Savusavu outpatients 
< 1yr 2.4 0.0 181 (49, 463) 0 (0, 143) 0.00 (0.00, 1.29) 0.045 
1–2yrs 2.4 1.5 181 (49, 463) 116 (24, 339) 0.64 (0.09, 3.79) 0.582 
3–4yrs 1.8 1.0 45 (9, 132) 26 (3, 93) 0.57 (0.05, 4.97) 0.708 
< 5yrs 6.6 2.5 100 (50, 178) 39 (13, 90) 0.39 (0.11, 1.21) 0.077 
RV = rotavirus. 
IRR = incidence rate ratio. 
a Population denominators are included in Supplementary Table 2. 
Fig. 1. Incidence rate ratios (post-rotavirus vaccine vs. pre-rotavirus vaccine introduction) for all-cause diarrhoea and all cause admissions and rotavirus diarrhoea CWMH 
admissions, Savusavu inpatients and Savusavu outpatients. An incidence rate ratio above one (the black line) represents an increase in incidence rate from the pre-rotavirus 



























een in the < 1 year age group (IRR = 0 • 10, 95%CI; 0 • 06–0 • 14, p -
alue < 0 • 001) and 1–2 years age group (IRR = 0 • 14, 95%CI; 0 • 09–
 • 21, p -value < 0 • 001) ( Table 3 , Fig. 1 and Supplementary Table 2).
here was an estimated 72% decline in infants ≤2 months of age 
IRR = 0 • 28, 95%CI; 0 • 03–1 • 38, p -value = 0 • 090) ( Fig. 1 and Supple-
entary Table 2). However, the confidence intervals were wide and 
panned one, as there were very few rotavirus cases in this age 
roup ( n = 10) and therefore considerable uncertainty around this 
stimate. The results of sensitivity analysis using multiple impu- 
ation to adjust for missing stool samples were similar although 
accine impact was slightly less; IRR = 0.18 (95%CI; 0.15, 0.24, p - 
alue < 0 • 001) among children < 5 years (Supplementary Table 2). 
Fig. 2 shows the peaks of rotavirus transmission pre-vaccine 
ere blunted in the post-rotavirus vaccine period. Fig. 3 shows the 5 ecline in the 3–4 years age group in 2012 and 2013, before this 
ge group were vaccinated. 
There was a 81% (95%CI; 51–94%, p -value < 0 • 001) decline in the
ase fatality rate (CFR) for all-cause diarrhoea admissions among 
hildren < 5 years at CWMH in the pre-rotavirus vaccine period 
CFR 2 • 6%, 95%CI; 1 • 9–3 • 5%) vs. in the post-rotavirus vaccine pe-
iod (CFR 0 • 5%, 95%CI; 0 • 2–1 • 2%). 
At Savusavu Hospital, rotavirus diarrhoea outpatient presenta- 
ions for children < 5 years showed an IRR of 0.39 (0.11–1.21, p - 
alue = 0.077) ( Table 3 and Supplementary Table 2). The results of 
ensitivity analysis using multiple imputation to adjust for miss- 
ng stool samples were IRR = 0.11 (95%CI; 0.04, 0.29, p -value < 0 • 001)
mong children < 5 years (Supplementary Table 2). The numbers of 
ases in this outcome were small ( n = 15). 
A.W.J. Jenney, R. Reyburn, F.T. Ratu et al. The Lancet Regional Health - Western Pacific 6 (2021) 10 0 053 
Fig. 2. Monthly admissions at Colonial War Memorial Hospital among children < 5 years of age for all-cause diarrhoea, rotavirus diarrhoea and the 12 months moving 
average for rotavirus diarrhoea, between January 2006 and December 2018. The rotavirus vaccine was introduced in October 2012. 













































The impact of rotavirus vaccine on rotavirus positive diarrhoea 
mong children < 5 years was similar among both ethnic groups. 
here was no evidence for an interaction between vaccine period 
nd ethnicity among children < 5 years ( p -value = 0.26); we there-
ore do not present ethnicity-stratified results. 
. Discussion 
This study from Fiji found a large reduction in rotavirus con- 
rmed diarrhoea in both hospital admissions and outpatient pre- 
entations in children < 5 years of age, after the introduction of the 
otavirus vaccine nationwide - the first such demonstration from a 
MIC in the Western Pacific. There was a reduction in mortality 
rom all-cause diarrhoea admissions in children < 5 years. In ad- 
ition, there were reductions in all-cause diarrhoea admissions in 
ge groups too young or too old to be vaccinated. 
There were demonstrable declines in both the severity (81% re- 
uction in mortality), the total burden of rotavirus ( > 80% decline) 
nd all-cause diarrhoea (36% decline) among children < 5 years. 
hese reductions were most likely due to the vaccine as rotavirus 
iarrhoeal outbreaks remained blunted for the five years after vac- 
ine introduction. Concurrent changes in patient admission policy 
nd management were not observed, evidenced by no decline in 
ll-cause admissions (the control group) except among infants ≤2 
onths old due to changes in admission criteria for newborns, un- 6 elated to diarrhoea. In Savusavu, outpatient presentations (though 
mall in number) fell, which indicate primary prevention through 
accination, as other interventions such as water, sanitation or hy- 
iene improvements did not occur during the study period. The 
ime series analysis in national all-cause diarrhoea among children 
 5 years showed a slightly greater decline (52%) to our IRR esti- 
ate with little evidence of a change in the background rate of 
iarrhoea. The > 80% reduction in rotavirus diarrhoea admissions 
mong children < 5 years of age observed in our study, is greater 
han that seen in Tanzania (65%) [20] , Japan (70%) [21] , Armenia 
69%) [22] and the Philippines (up to 63%) [11] , although simi- 
ar to Thailand (88%) [23] . This is likely due to the high, full-dose 
two doses) vaccine coverage and, perhaps, the lower rates of mal- 
utrition and gut enteropathy than those seen in countries like 
otswana where vaccine effectiveness is lower [24] . 
The greatest reduction in rotavirus diarrhoea and all-cause di- 
rrhoea admissions was among infants < 1 year which was sus- 
ained into the second year of life. A systematic review of 58 post- 
icensure studies showed vaccine effectiveness tended to decline in 
he second year, particularly in medium- and high-mortality set- 
ings [25] . Suggested reasons include the placebo group achieving 
mmunity through natural infection, accelerated waning of immu- 
ity, and co-infection with a second pathogen [26] . Timing of the 
accine doses may also account for this. While usually given at six 
nd 10 weeks, doses at two weeks and four months (as in Bo- 







































































































ivia), led to a measurable (though not quite statistically signifi- 
ant) improvement in vaccine effectiveness [27] . In addition, the 
ighly variable mixing/contact patterns in potentially large house- 
olds may elicit indirect effects on transmission of rotavirus, thus 
mpacting vaccine effectiveness [28] . 
This study provides evidence of reductions in diarrhoea among 
oth unvaccinated children and adults in a middle-income setting. 
ther studies illustrating this are mostly in high-income countries 
HIC) including Saudi Arabia [29] , the USA [ 30 , 31 ]. In poorer coun-
ries this is rare but has been reported, eg. Rwanda [32] . We also
ound a 70% decline in rotavirus diarrhoea admissions among the 
nfants too young to be vaccinated. While cases were few in Fiji, it 
s an important public health finding regarding vulnerable infants 
ess than 6 weeks old. Further protection may come with the RV3- 
B vaccine, as a phase III clinical trial in Indonesian neonates vac- 
inated within the first five days of life demonstrated 75% vaccine 
fficacy against severe rotavirus gastroenteritis to 12 months com- 
ared to 51% with the routine infant two dose schedule at eight 
nd 14 weeks [33] . The RV3-BB vaccine will also address the host 
elated genetic resistance in some human populations to P[6] virus. 
In Fijian outpatients aged < 5 years, rotavirus diagnosis did not 
ecline with the primary analysis using complete case data but 
id decline with the sensitivity analysis using multiple imputation. 
here were very few cases, particularly in the post-rotavirus vac- 
ine period and therefore IRR were very sensitive to changes in 
ase numbers. Other countries, including the Philippines [11] and 
imbabwe [34] , have demonstrated a reduction in outpatient ro- 
avirus diarrhoea. While, most studies assess rotavirus impact 
n inpatient presentations, outpatients bear the greatest burden. 
he rural setting for our outpatient study, Savusavu, had lower 
re-vaccination rates of rotavirus diarrhoea than the capital Suva 
perhaps due to other, undiagnosed gastrointestinal pathogens) 
onetheless the vaccine’s impact was apparent. 
.1. Limitations 
As with all observational studies, causality (reduction of diar- 
hoea) cannot be ascribed to the introduction of rotavirus vaccine. 
here were other interventions which may have contributed to our 
ndings - including the introduction of the World Health Organiza- 
ion’s (WHO) integrated management for childhood illness (IMCI) 
n the later years of the study. However, any improvement in case 
anagement would not reduce the number of outpatient rotavirus 
iarrhoea cases as seen in our study. We were not able to assess 
he dose effect as coverage was high throughout Fiji and there is 
uch population movement. We only included the nation’s largest 
ospital (CWMH) and one (small) secondary hospital, missing sev- 
ral large and many smaller facilities. We only recorded the in- 
ospital deaths - most paediatric deaths occur in hospital but the 
dult deaths (for which we did not assess vaccine impact) may 
ave been underestimated. Additionally, stool collection rates var- 
ed by vaccine introduction period which may have introduced bias 
n the period with low collection rates. To address this, we used 
ultiple imputation as a sensitivity analysis, and coupled with the 
lunting in rotavirus seasonality we believe our findings show sup- 
ortive evidence that rotavirus vaccine contributed to the reduc- 
ions in diarrhoea in the post- rotavirus vaccine period. We have 
emoved readmissions within 30 days however we have not ad- 
usted for repeat episodes of hospitalisation in our analysis. 
.2. Conclusion 
Fiji is the first upper-middle-income country in the Pacific is- 
and region to show a decline in the burden of rotavirus diarrhoea, 
nd all-cause diarrhoea admissions in all ages and mortality in 7 hildren after rotavirus vaccine introduction. While improved out- 
atient management practices (WHO IMCI) may have contributed 
o the decline in diarrhoea, the temporal relationship to vaccine 
ntroduction is compelling. The reduction in diarrhoea admissions 
s likely to have resulted in a considerable reduction of the work- 
oad for the health system and therefore reduced costs for manag- 
ng this condition. In addition, in this setting we have found that 
accine protection continues into the second year of life. 
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